Major VC Rounds For AI-driven Biotechs in 2020

by Andrii Buvailo, PhD          Biopharma insight / Biopharma Insights

Disclaimer: All opinions expressed by Contributors are their own and do not represent those of their employers, or
Contributors are fully responsible for assuring they own any required copyright for any content they submit to This website and its owners shall not be liable for neither information and content submitted for publication by Contributors, nor its accuracy.

   5691    Comments 0
Share:   Share in LinkedIn  Share in Reddit  Share in X  Share in Hacker News  Share in Facebook  Send by email

The ongoing COVID19 crisis forced biotech-oriented venture capitalists (VC) to somewhat slow down the pace of their usual deal-flow -- according to data by PitchBook biopharma venture deals in 2020 are down roughly 16% compared to last year. 

However, there is still a lot going on in drug discovery and healthcare, and here I would like to specifically focus on artificial intelligence (AI)-driven biotech and health tech startups who managed to raise notable rounds in 2020, so far (based on our report “A Landscape of Artificial Intelligence (AI) In Drug Discovery and Development”). The deals are ordered by the amount of money raised 





San Francisco-based data-driven drug discovery company Insitro has recently raised $143M in Series B financing, led by Andreessen Horowitz, CPP Investments, and others. Founded in 2018 and led by a computer science star and Coursera co-founder Dr. Daphne Koller, Insitro already secured a strategic drug discovery collaboration with Gilead last year. The company is focused on advancing the development of ML-driven disease models predictive of human clinical outcomes and applying those models for Insitro’s first two therapeutic areas in liver and CNS diseases. 



In March, announced Financing. The investors include Baillie Gifford, Franklin Templeton, NEA, Novo Holdings, and funds and accounts managed by T. Rowe Price. The company’s main focus is advancing precision medicine and applying AI in healthcare, and it claims to possess the largest clinical and molecular data library. With the additional funding, Tempus continues to expand its operations to various diseases areas, including diabetes, depression, and cardiology. Since its foundation in 2015, the company has raised a total of $620M.

Continue reading

This content available exclusively for BPT Mebmers

Topics: Emerging Technologies    Biotech Companies   

Share:   Share in LinkedIn  Share in Reddit  Share in X  Share in Hacker News  Share in Facebook  Send by email


There are no comments yet. You can be the first.

Leave a Reply

Your email address will not be published. Required fields are marked *